Neurosurgery of The First Affiliated Hospital, Jinan University, Guangzhou, China.
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
J Clin Neurosci. 2024 Feb;120:196-203. doi: 10.1016/j.jocn.2024.01.018. Epub 2024 Jan 25.
We retrospectively analyzed the effects of low-dose bevacizumab (BEV) combined with temozolomide (TMZ) on health-related quality of life (HRQL) in patients with recurrent high-grade glioma (rHGG).
A total of 129 patients with rHGG were included in this study. Patients were divided into a combination group and TMZ group based on the treatment they received. The Quality of Life Questionnaire Core 30 (QLQ-C30) and EORTC Brain Cancer Module (QLQ-BN20) were used to evaluate HRQL in all patients before and after treatment. Categorical variables were compared using the chi-squared test. The data for all continuous variables were first tested for a normal distribution. If the data conformed to a normal distribution, a T test was used for comparison. If the data did not conform to a normal distribution, the rank-sum test was used.
There were differences in PFS and PFS-6 between the BEV + TMZ and TMZ groups (P＜0.05). However, there was no difference in the OS between the two groups (P＞0.05). The BEV + TMZ group performed better than the TMZ group in both the QLQ-C30 and QLQ-BN20. In addition, the KPS score was higher in the BEV + TMZ group than in the TMZ group. Steroid doses given were lower in the BEV + TMZ group than in the TMZ group (P < 0.05).
Low-dose BEV + TMZ can relieve the clinical symptoms of rHGG patients, reduce their steroid dose, improve HRQL, and prolong PFS, but does not bear any benefit on OS.
我们回顾性分析了低剂量贝伐珠单抗（BEV）联合替莫唑胺（TMZ）治疗复发性高级别胶质瘤（rHGG）患者的健康相关生活质量（HRQL）的影响。
本研究共纳入 129 例 rHGG 患者。根据治疗方法，患者分为联合组和 TMZ 组。所有患者在治疗前后均采用生活质量问卷核心 30 项（QLQ-C30）和 EORTC 脑癌模块（QLQ-BN20）评估 HRQL。采用卡方检验比较分类变量。所有连续变量数据首先进行正态分布检验。如果数据符合正态分布，则采用 T 检验进行比较。如果数据不符合正态分布，则采用秩和检验。
BEV+TMZ 组和 TMZ 组在 PFS 和 PFS-6 方面存在差异（P＜0.05）。然而，两组的 OS 无差异（P＞0.05）。BEV+TMZ 组在 QLQ-C30 和 QLQ-BN20 方面的表现均优于 TMZ 组。此外，BEV+TMZ 组的 KPS 评分高于 TMZ 组。与 TMZ 组相比，BEV+TMZ 组的激素剂量更低（P<0.05）。
低剂量 BEV+TMZ 可缓解 rHGG 患者的临床症状，降低其激素剂量，提高 HRQL，延长 PFS，但对 OS 无获益。
